Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Page 1
Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
Thornton CS, Caverly LJ, Kalikin LM, Carmody LA, McClellan S, LeBar W, Sanders DB, West NE, Goss CH, Flume PA, Heltshe SL, VanDevanter DR, LiPuma JJ. Thornton CS, et al. Among authors: flume pa. Ann Am Thorac Soc. 2024 Apr;21(4):595-603. doi: 10.1513/AnnalsATS.202306-576OC. Ann Am Thorac Soc. 2024. PMID: 37963297 Clinical Trial.
Virus positivity was associated with reduced risk of future PEx (hazard ratio, 0.82; 95% confidence interval, 0.69-0.99; P = 0.034) and longer median time to next PEx (255 d vs. 172 d; P = 0.021) compared with virus negativity.Conclusions: More than one-third of STOP2 participant …
Virus positivity was associated with reduced risk of future PEx (hazard ratio, 0.82; 95% confidence interval, 0.69-0.99; P = 0.034) and long …
Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections.
Mingora CM, Bullington W, Faasuamalie PE, Levin A, Porter G, Stadnick R, Varley CD, Addrizzo-Harris D, Daley CL, Olivier KN, Winthrop KL, Dorman SE, Flume PA. Mingora CM, et al. Among authors: flume pa. Open Forum Infect Dis. 2023 Jul 3;10(7):ofad335. doi: 10.1093/ofid/ofad335. eCollection 2023 Jul. Open Forum Infect Dis. 2023. PMID: 37476076 Free PMC article.
This study reports clinical experience with omadacycline for treatment of M abscessus infections at five large nontuberculous mycobacterial (NTM) disease clinics across the United States to better understand long-term safety and tolerability. METHODS: We conducted a multic …
This study reports clinical experience with omadacycline for treatment of M abscessus infections at five large nontuberculous mycobacterial …
Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial.
Flume PA, Harris RS, Paz-Diaz H, Ahluwalia N, Higgins M, Campbell D, Berhane I, Shih JL, Sawicki G. Flume PA, et al. J Cyst Fibros. 2023 May;22(3):464-470. doi: 10.1016/j.jcf.2022.12.006. Epub 2022 Dec 27. J Cyst Fibros. 2023. PMID: 36581484 Clinical Trial.
BACKGROUND: Study 661-110 (EXTEND) is a phase 3, open-label, three-part rollover study designed to assess the long-term safety and efficacy of tezacaftor/ivacaftor (TEZ/IVA) in participants aged 12 years homozygous for F508del (F/F) or heterozygous for F508del and a residu …
BACKGROUND: Study 661-110 (EXTEND) is a phase 3, open-label, three-part rollover study designed to assess the long-term safety and ef …
Inhaled nitric oxide for adults with pulmonary non-tuberculous mycobacterial infection.
Flume PA, Garcia BA, Wilson D, Steed L, Dorman SE, Winthrop K. Flume PA, et al. Respir Med. 2023 Jan;206:107069. doi: 10.1016/j.rmed.2022.107069. Epub 2022 Dec 2. Respir Med. 2023. PMID: 36493605
Participants were treated with gNO for 50 min three times daily, five days per week, for three weeks (total of 15 treatment days). RESULTS: Ten participants, of whom nine were on long-term NTM antibiotic therapy, were enrolled. All participants completed the regimen withou …
Participants were treated with gNO for 50 min three times daily, five days per week, for three weeks (total of 15 treatment days). RESULTS: …
Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion.
Mingora CM, Garcia BA, Mange KC, Yuen DW, Ciesielska M, van Ingen J, Flume PA, Dorman SE. Mingora CM, et al. Among authors: flume pa. BMC Infect Dis. 2022 Mar 12;22(1):246. doi: 10.1186/s12879-022-07250-4. BMC Infect Dis. 2022. PMID: 35279081 Free PMC article.
BACKGROUND: Mycobacterial time to positivity (TTP) in liquid culture media has predictive value for longer term outcomes in pulmonary tuberculosis, but has not been thoroughly studied in nontuberculous mycobacterial pulmonary disease. ...
BACKGROUND: Mycobacterial time to positivity (TTP) in liquid culture media has predictive value for longer term outcomes in pulmonary …
Improvements in anthropometric measures and gastrointestinal tolerance in patients with cystic fibrosis by using a digestive enzyme cartridge with overnight enteral nutrition.
Hendrix SJ, Flume PA, First ER, Stone AA, Van Buskirk M. Hendrix SJ, et al. Among authors: flume pa. Nutr Clin Pract. 2022 Apr;37(2):344-350. doi: 10.1002/ncp.10831. Epub 2022 Feb 24. Nutr Clin Pract. 2022. PMID: 35199869 Free PMC article.
Enteral nutrition (EN) is used to supplement caloric intake and requires pancreatic enzyme replacement for effective digestion. We evaluated the relationship between long-term use of an in-line digestive enzyme cartridge with EN and changes in anthropometric measures and G …
Enteral nutrition (EN) is used to supplement caloric intake and requires pancreatic enzyme replacement for effective digestion. We evaluated …
Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis.
Elborn JS, Flume PA, Van Devanter DR, Procaccianti C. Elborn JS, et al. Among authors: flume pa. Future Microbiol. 2021 Sep;16:1087-1104. doi: 10.2217/fmb-2021-0150. Epub 2021 Aug 13. Future Microbiol. 2021. PMID: 34384254 Free article. Review.
By adulthood, chronic Pseudomonas aeruginosa (Pa) is the most prevalent infective organism and is difficult to eradicate owing to its adaptation to the CF lung microenvironment. Long-term suppressive treatment with inhaled antimicrobials is the standard care for reducing e …
By adulthood, chronic Pseudomonas aeruginosa (Pa) is the most prevalent infective organism and is difficult to eradicate owing to its adapta …
Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure.
Griffith DE, Thomson R, Flume PA, Aksamit TR, Field SK, Addrizzo-Harris DJ, Morimoto K, Hoefsloot W, Mange KC, Yuen DW, Ciesielska M, Wallace RJ Jr, van Ingen J, Brown-Elliott BA, Coulter C, Winthrop KL; CONVERT Study Group. Griffith DE, et al. Among authors: flume pa. Chest. 2021 Sep;160(3):831-842. doi: 10.1016/j.chest.2021.03.070. Epub 2021 Apr 19. Chest. 2021. PMID: 33887244 Free article. Clinical Trial.
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080
Here, we present results of study 661-110 (EXTEND), a 96-week open-label extension study that assessed long-term safety, tolerability, and efficacy of tezacaftor-ivacaftor in participants aged 12 years or older with cystic fibrosis who were homozygous or heterozygous for t …
Here, we present results of study 661-110 (EXTEND), a 96-week open-label extension study that assessed long-term safety, tolerability …
Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.
Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS. Flume PA, et al. J Cyst Fibros. 2018 Jan;17(1):83-88. doi: 10.1016/j.jcf.2017.06.002. Epub 2017 Jun 24. J Cyst Fibros. 2018. PMID: 28651844 Free article.
Short-term recovery was measured 2 to 8weeks after treatment, and long-term recovery was determined at the end-of-study, both compared with baseline measured just prior to the PEx. RESULTS: Fewer patients receiving ivacaftor experienced a PEx than patients receiving …
Short-term recovery was measured 2 to 8weeks after treatment, and long-term recovery was determined at the end-of-study, both …
18 results